Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
Unternehmens-codeSLGL
Name des UnternehmensSol Gel Technologies Ltd
IPO-datumFeb 01, 2018
Gegründet am1997
CEO- -
Anzahl der mitarbeiter34
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 01
AddresseGolda Meir 7
StadtNESS-ZIONA
BörseNASDAQ Capital Market Consolidated
LandIsrael
Postleitzahl- -
Telefon97289313433
Websitehttp://www.sol-gel.com
Unternehmens-codeSLGL
IPO-datumFeb 01, 2018
Gegründet am1997
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten